BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12015746)

  • 1. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival.
    Strizzi L; Muraro R; Vianale G; Natoli C; Talone L; Catalano A; Mutti L; Tassi G; Procopio A
    J Pathol; 2002 Jun; 197(2):218-23. PubMed ID: 12015746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
    Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
    Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
    Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.
    Strizzi L; Catalano A; Vianale G; Orecchia S; Casalini A; Tassi G; Puntoni R; Mutti L; Procopio A
    J Pathol; 2001 Apr; 193(4):468-75. PubMed ID: 11276005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and origin determination of malignant pleural effusions through the use of the breast cancer marker human mammaglobin.
    Roncella S; Ferro P; Franceschini MC; Bacigalupo B; Dessanti P; Sivori M; Carletti AM; Fontana V; Canessa PA; Pistillo MP; Fedeli F
    Diagn Mol Pathol; 2010 Jun; 19(2):92-8. PubMed ID: 20502186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of integrin-linked kinase in the serum of patients with malignant pleural mesothelioma.
    Watzka SB; Posch F; Pass HI; Huflejt M; Bernhard D; Hannigan GE; Müller MR
    J Thorac Cardiovasc Surg; 2011 Aug; 142(2):384-9. PubMed ID: 21620418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
    Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
    Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
    Ylagan LR; Zhai J
    Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis.
    Strizzi L; Vianale G; Catalano A; Muraro R; Mutti L; Procopio A
    Int J Oncol; 2001 May; 18(5):1093-8. PubMed ID: 11295061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients.
    Marchetti A; Tinari N; Buttitta F; Chella A; Angeletti CA; Sacco R; Mucilli F; Ullrich A; Iacobelli S
    Cancer Res; 2002 May; 62(9):2535-9. PubMed ID: 11980646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotensin expression and outcome of malignant pleural mesothelioma.
    Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
    Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma.
    Ohta Y; Shridhar V; Kalemkerian GP; Bright RK; Watanabe Y; Pass HI
    Cancer; 1999 Jun; 85(12):2570-6. PubMed ID: 10375104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
    Klech H; Rona G; Hutter C; Bayer PM; Kummer F
    Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. A study of 207 patients.
    Villena V; López-Encuentra A; Echave-Sustaeta J; Martín-Escribano P; Ortuño-de-Solo B; Estenoz-Alfaro J
    Cancer; 1996 Aug; 78(4):736-40. PubMed ID: 8756365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications.
    Fiorelli A; Vicidomini G; Di Domenico M; Napolitano F; Messina G; Morgillo F; Ciardiello F; Santini M
    Interact Cardiovasc Thorac Surg; 2011 Mar; 12(3):420-4. PubMed ID: 21172937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
    Esposito V; Baldi A; De Luca A; Claudio PP; Signoriello G; Bolognese A; Centonze P; Giordano GG; Caputi M; Baldi F; Giordano A
    Anticancer Res; 1997; 17(1B):733-6. PubMed ID: 9066611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
    O'Kane SL; Cawkwell L; Campbell A; Lind MJ
    Eur J Cancer; 2005 Jul; 41(11):1645-8. PubMed ID: 15964184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.